Lily A. Brown, PhD, describes a patient with generalized anxiety disorder (GAD) who sought urgent consultation despite prior evaluations by multiple clinicians internationally. The patient’s continued ...

Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of ...

Dr Bradley N. Gaynes reflects on how the understanding and treatment of generalized anxiety disorder (GAD) has evolved over the past three decades. One major advance has been the improved ability to ...

Individuals with generalized anxiety disorder (GAD), a condition characterized by daily excessive worry lasting at least six months, have a high relapse rate even after receiving treatment. Artificial ...

Earlier this month, Definium Therapeutics reported results from a large U.S. healthcare claims study of more than 1.27 ...

In a world of constant connectivity and mounting pressures, generalized anxiety disorder (GAD) has emerged as a significant mental health challenge affecting millions. Recent studies show that anxiety ...

Ashwini Nadkarni, MD, of Mass General Brigham, discusses what’s new in the management of generalized anxiety disorder.

Anxiety feels like your mind never shuts off and your body never gets to rest. It's not “just worry”, it’s living in constant ...

Anxiety disorders are a group of disorders that share symptoms like excessive fear and heightened stress (American Psychological Association [APA], 2022). It is important to note that fear and anxiety ...

NEW YORK--(BUSINESS WIRE)--Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product ...